VANCOUVER: A team of Canadian researchers has pioneered a revolutionary test that enhances the diagnosis of aggressive medulloblastoma, the most common malignant brain tumor in children. This breakthrough could spare young patients from unnecessary treatments and their harmful long-term side effects, while ensuring high-risk cases receive the intensive therapy they need.
The innovative technique, developed by experts from the University of British Columbia (UBC), BC Cancer, and BC Children’s Hospital, allows doctors to tailor treatments based on individual tumor types. Unlike existing diagnostic methods, which rely on complex and costly genetic testing, this new approach can be implemented using widely available laboratory technology—making it accessible to hospitals worldwide.
A Simple Yet Powerful Breakthrough
“This test will enable hospitals to identify high-risk medulloblastoma cases swiftly, ensuring more children receive precise and effective treatment based on their tumor profile,” said Dr. Alberto Delaidelli, first author of the study and a postdoctoral fellow in the laboratory of Dr. Poul Sorensen, a distinguished scientist at BC Cancer and investigator with the Michael Cuccione Childhood Cancer Research Program at BC Children’s Hospital.
The findings, recently published in Neuro-Oncology, mark a significant advancement in pediatric cancer care. Medulloblastoma affects approximately 500 children annually in Canada and the U.S., making accurate diagnosis and personalized treatment a top priority in pediatric oncology.
Identifying High-Risk Tumors with MYC Protein
Currently, all children diagnosed with medulloblastoma undergo similar treatment regimens, including surgery, chemotherapy, and radiation therapy. However, radiation can cause severe long-term side effects, such as learning disabilities and developmental delays, particularly in young patients.
Dr. Sorensen’s research team revolutionized tumor classification by using proteomics—a technique that analyzes the entire protein spectrum within cells to uncover biological markers of disease. Their study identified MYC, a protein found at elevated levels in the most aggressive medulloblastoma cases.
By applying immunohistochemistry (IHC), a standard lab technique, to nearly 400 tumor samples, researchers confirmed that MYC-positive tumors are far more likely to relapse and resist treatment. This discovery enables doctors to accurately determine which patients require intensive therapy and which can safely avoid radiation, reducing unnecessary exposure to harmful side effects.
Immediate Clinical Impact: A Global Step Forward
Unlike traditional genetic tests that take weeks to process and require specialized facilities, the MYC test can be performed in a single day by any standard pathology lab.
“Our test offers a practical, cost-effective, and rapid solution for hospitals worldwide,” explained Dr. Sorensen. “With no need for expensive equipment or long delays, we can now provide better, faster care for children battling brain tumors.”
The study is a global collaboration, involving researchers from Vancouver, Toronto, Montreal, Winnipeg, Hamilton, Halifax, and Heidelberg, Germany. Given that IHC is already a routine diagnostic practice worldwide, the new test could be rapidly adopted across hospitals, transforming the way medulloblastoma is diagnosed and treated.
With this breakthrough, personalized treatment for childhood brain tumors is becoming a global reality, offering hope for better outcomes and improved quality of life for young cancer patients.